Forte Biosciences Inc., a clinical-stage biopharmaceutical company specializing in autoimmune and autoimmune-related diseases, has announced positive results from its Phase 1b trial for FB102 in the treatment of celiac disease. The study, which involved 32 subjects, demonstrated a significant improvement for those treated with FB102 compared to the placebo group. The trial reported a 73% improvement in the Vh:Cd ratio and a 42% reduction in gluten challenge-induced gastrointestinal symptoms for FB102-treated subjects. No dropouts or severe adverse events were reported. Forte Biosciences is set to initiate a Phase 2 celiac disease trial, with a topline readout expected in 2026. The results from the Phase 1b study were discussed in a conference call hosted by Forte Biosciences, featuring Prof. Jason Tye-Din, the principal investigator of the study.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。